Status:
ACTIVE_NOT_RECRUITING
Meningococcal Vaccination in Patients on Complement Inhibitors
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Myasthenia Gravis Generalised
Vaccination
Eligibility:
All Genders
18+ years
Brief Summary
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies directed predominantly against components of the postsynaptic membrane of the neuromuscular junction. Anti-aquaporin-4...
Eligibility Criteria
Inclusion
- Study Participant must be ≥ 18 years old;
- Diagnosis of anti-AChR positive generalized Myasthenia Gravis or Positive anti-AQP4 NMOSD;
- Need for therapy with complement inhibitor drugs according to the therapeutic indications approved by AIFA;
- Possibility of follow-up in the reference centre;
- Signing of the Informed Consent to the Study.
Exclusion
- Age \< 18 years;
- Poor Compliance with Drug Therapy
- Insufficient availability of Clinical Information;
- Current Neoplasm or Infection at the Time of Collection of Biological Samples;
- Refusal to Sign the Informed Consent to the Study
Key Trial Info
Start Date :
March 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06906692
Start Date
March 25 2025
End Date
April 1 2027
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico A. Gemelli IRCCS
Rome, RM, Italy, 00168